ACW Appendix 4E and 2026 annual report
Filed with ASX · · 88 pages · English
Summary by 6ix AI
The company reported a decrease in revenue from ordinary activities compared to the previous year, alongside a notable increase in total expenses due to ramped-up clinical activities. Actinogen is developing Xanamem, a novel therapy aimed at treating Alzheimer’s disease and other neurological conditions, with pivotal trial results expected soon.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Actinogen Medical Limited on 6ix
Earlier from Actinogen Medical
- Appendix 4G
- Corporate Governance Statement
- Appendix 3Y - Dr George Morstyn
- Application for quotation of securities - ACW
- Appendix 3Y-Malcolm McComas
Later from Actinogen Medical
- ACW FY2026 results and outlook
- Appendix 3Y-Dr Geoffrey Brooke
- Proposed issue of securities - ACW
- ACW unlisted options fully underwritten
- Response to ASX Price Query
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical